Physician profile
Marcus Lackey
NPI 1326743030
$2,033.74
in general payments reported to CMS, 2019-2025
15 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $78.61 · 2024: $411 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $255.19 | 2024-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $244.46 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $228.37 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $221.76 | 2025 | Cobenfy |
| Corium, LLC | $217.78 | 2024-2025 | Azstarys |
| Alkermes, INC. | $169.86 | 2023-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $150.98 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $137.73 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $134.71 | 2024-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $85.35 | 2025 | Qelbree |
| Abbvie INC. | $63.37 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.51 | 2024 | Caplyta |
| Alexion Pharmaceuticals, INC. | $30.82 | 2023 | Ultomiris |
| Lundbeck LLC | $23.39 | 2024 | Rexulti |
| Neos Therapeutics, LP | $14.46 | 2025 | Exxua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Lackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.